Literature DB >> 7916934

Nodular regenerative hyperplasia: a controversial indication for orthotopic liver transplantation.

H A Elariny1, S S Mizrahi, D H Hayes, J P Boudreaux, J L Hussey, G H Farr.   

Abstract

Nodular regenerative hyperplasia of the liver is an uncommon cause of portal hypertension. Patients with nodular regenerative hyperplasia have signs and symptoms of portal hypertension, without evidence of hepatocellular failure or encephalopathy. We report the case of a 44-year-old woman with recurrent esophageal bleeding and refractory ascites who had a history of hemosiderosis, hepatitis C, and chronic renal allograft rejection. Our preoperative diagnosis was cirrhotic end-stage liver disease and end-stage renal disease for which the patient underwent combined hepatic and renal transplantation. Her portal hypertension symptoms resolved, and her renal function has been normal for 18 months of follow-up. Histologic examination of the liver revealed nodular regenerative hyperplasia, and a review of the literature regarding the surgical management of patients with nodular regenerative hyperplasia revealed that various shunting procedures are generally recommended. After the failure of medical management in patients with nodular regenerative hyperplasia, portosystemic shunting may be indicated before proceeding to hepatic transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916934     DOI: 10.1007/bf00327162

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  8 in total

1.  Noncirrhotic portal fibrosis: a rare cause of end-stage liver disease requiring liver transplantation.

Authors:  Sunil Taneja; Yogesh Chawla; Radha K Dhiman
Journal:  Hepatol Int       Date:  2011-09-03       Impact factor: 6.047

2.  Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.

Authors:  G Vernier-Massouille; J Cosnes; M Lemann; P Marteau; W Reinisch; D Laharie; G Cadiot; Y Bouhnik; M De Vos; A Boureille; B Duclos; P Seksik; J-Y Mary; J-F Colombel
Journal:  Gut       Date:  2007-05-15       Impact factor: 23.059

3.  Nodular regenerative hyperplasia related portal hypertension in a patient with hypogammaglobulinaemia.

Authors:  Barun Kumar Lal; Adrian Stanley
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

Review 4.  Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.

Authors:  Marek Hartleb; Krzysztof Gutkowski; Piotr Milkiewicz
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

5.  Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20-year cohort study in all Dutch liver transplant units.

Authors:  Berrie Meijer; Melek Simsek; Hans Blokzijl; Robert A de Man; Minneke J Coenraad; Gerard Dijkstra; Carin Mj van Nieuwkerk; Chris Jj Mulder; Nanne Kh de Boer
Journal:  United European Gastroenterol J       Date:  2016-11-16       Impact factor: 4.623

6.  Familial occurrence of nodular regenerative hyperplasia of the liver: a report on three families.

Authors:  J Dumortier; O Boillot; M Chevallier; F Berger; P Potier; P J Valette; P Paliard; J Y Scoazec
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

7.  Acute deterioration of idiopathic portal hypertension requiring living donor liver transplantation: a case report.

Authors:  Takamitsu Inokuma; Susumu Eguchi; Tetsuo Tomonaga; Kensuke Miyazaki; Koji Hamasaki; Hirotaka Tokai; Masaaki Hidaka; Kosho Yamanouchi; Mitsuhisa Takatsuki; Sadayuki Okudaira; Yoshitsugu Tajima; Takashi Kanematsu
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

Review 8.  Living donor liver transplantation for idiopathic portal hypertension with extrahepatic portal vein stenosis and splenic artery aneurysms: a case report and review of the literature.

Authors:  Shigeyuki Kawachi; Naokazu Chiba; Masashi Nakagawa; Toshimichi Kobayashi; Kosuke Hikita; Toru Sano; Koichi Tomita; Hiroshi Hirano; Yuta Abe; Hideaki Obara; Motohide Shimazu
Journal:  BMC Surg       Date:  2020-10-29       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.